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Physical and biological range uncertainties limit the clinical potential
of Proton Beam Therapy (PBT). In this proceedings, we report on two
research projects, which we are conducting in parallel and which both
tackle the problem of range uncertainties. One aims at developing software
tools and the other at developing detector instrumentation. Regarding the
first, we report on our development and pre-clinical application of a GPU-
accelerated Monte Carlo (MC) simulation toolkit Fred. Concerning the
letter, we report on our investigations of plastic scintillator based PET de-
tectors for particle therapy delivery monitoring. We study the feasibility
of Jagiellonian-PET detector technology for proton beam therapy range
monitoring by means of MC simulations of the β+ activity induced in a
phantom by proton beams and present preliminary results of PET image
reconstruction. Using a GPU-accelerated Monte Carlo simulation toolkit
Fred and plastic scintillator based PET detectors we aim to improve pa-
tient treatment quality with protons.
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Physics, June 23 – 28, 2019 in Collegium Maius, Krako´w, Poland
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1. Introduction
The increasing numbers of proton facilities and successful proton treat-
ments [1] indicate that the relevance of Proton Beam Therapy (PBT) as
technique for tumor radiation therapy is a rapidly growing. Krako´w proton
facility is in clinical operation since Oct. 2016 and more than 10 patients a
day are currently treated.
Range uncertainties, i.e. uncertainty of the distance that protons travel
inside patient body, currently represent one of the biggest caveats for the
exploitation of the full potential of proton therapy treatments [2]. Proton
beams range is particularly affected by biological and physical uncertain-
ties in a heterogeneous patient body. Therefore, to assure target coverage,
medical physicists currently apply up to about 1 cm safety margins around
the tumor volume, which lead to the unwanted irradiation of the healthy
tissues surrounding the tumor [2].
The biological dose, DRBE expressed in Gy(RBE), delivered to the pa-
tient is the actual quality of clinical interest. It is calculated as DRBE =
D×RBE, where D is the physical dose expressed in Gy and RBE is the
Relative Biological Effectiveness. By definition, in conventional therapy
with photons RBE= 1.0 therefore, physical and biological doses are equal
and correlated with clinical response. Protons have an increased biological
effectiveness compared to photons, i.e. RBE is larger than one. Currently
in clinical routine, the RBE of protons is assumed to be constant and equal
to 1.1 [3]. This convention neglects complex, often nonlinear dependency of
the RBE on such parameters as penetration depth, Linear Energy Transfer
(LET), dose, fractionation scheme, tissue type and endpoint, cell cycle phase
or oxygenation level. These dependencies might affect the effective proton
range, i.e., introduce biological range uncertainty and thus affect the dose to
the surrounding tissue and Organs at Risk (OAR). Modification of proton
physical dose by RBE, which is an uncertain weighting factor, makes the
correlation of proton biological dose and clinical effect of tumor irradiation
uncertain, and unification of clinical studies comparing the effectiveness of
different radiation modalities challenging.
An improvement resulting from correctly applying radiobiological as-
sumptions in PBT could be achieved only under the condition that the
physical dose is accurately delivered to the patient. In fact, physical range
uncertainties, occurring due to patient mispositioning or Computed Tomog-
raphy (CT) scanner calibration introducing Hounsfield Unit (HU) to stop-
ping power conversion, could cause differences between treatment plan and
treatment delivery. Monte Carlo simulations and range monitoring methods
are essential in PBT to guarantee that the physical dose is accurately deliv-
ered and therefore to reduce the biological and physical range uncertainties
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in a patient body.
Fig. 1 illustrates which role could play each of the two topics reported
in this manuscript in the clinical treatment workflow.
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Fig. 1. Diagram of standard patient treatment protocol (blue colors) along with
activities of our group (orange color) aiming to improve PBT quality. We incorpo-
rate advanced nuclear physics computational and experimental methods to predict
physical and biological dose in patient more accurately and to monitor proton beam
range in patient by means of PET imaging.
2. Monte Carlo simulations to address physical and biological
range uncertainties of proton beams
It is recognized that Monte Carlo (MC) methods can offer improved dose
calculation accuracy in heterogeneous media and therefore predict more ac-
curately therapeutic dose distributions in patients compared to the ana-
lytical algorithms that are typically employed in the Treatment Planning
Systems (TPS) used in clinical routine [2]. Nowadays, the use of a variable
RBE is being discussed among the PBT scientific community. We perform
biological dose calculations with variable RBE and investigate biological
range uncertainties by means of MC simulations of patient CT images ex-
ploiting the MC dose calculation tool Fred [4, 5]. Fred offers a unique
combination of features: accuracy of a MC code including biological dose
computation, flexibility of a research tool, and high dose calculation speed
due to GPU-acceleration. These characteristics are impossible to achieve
with the currently available commercial TPS and general purpose MC codes
like Geant4/FLUKA [6, 7].
We have successfully implemented in Fred the proton beam model used
clinically for patient treatment in the Krako´w facility. The Integrated Depth
Dose profiles (IDD) of single proton pencil beams in water simulated with
Fred MC code for different energies are in excellent agreement with the
IDDs obtained during the commissioning measurements (see fig. 2 left),
showing differences of less than 2%.
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The emittance model, describing lateral beam propagation in air, was imple-
mented in Fred, in accordance with the clinical system. The longitudinal
and lateral pencil beam shapes are modelled in Fred MC with a submil-
limeter precision.
We validated the beam model experimentally using the transversal pa-
tient treatment plan verification measurements. Such measurements are
routinely performed by medical physicists for treatment plan quality assur-
ance with an array of 1020 ionization chambers (MatriXX IBA) placed in a
water phantom. A transversal dose plane extracted from Fred MC and the
dose distribution measured with the MatriXX detector at the same depth
in water, as well as the Gamma Index (GI) map obtained from GI test are
presented in fig. 2. The GI passing rate (3%/2 mm criteria) greater than
98% was obtained for 182 dose plane measurements for 10 patients. Based
on these results, we can assure that dose distributions of clinical treatment
plans can be recalculated accurately.
60 40 20 0 20 40 60
X [mm]
60
40
20
0
20
40
60
Y 
[m
m
]
Fred MC simulation
0.0 0.2 0.4 0.6 0.8 1.0
Dose [Gy]
60 40 20 0 20 40 60
X [mm]
60
40
20
0
20
40
60
Y 
[m
m
]
MatriXX measurement
0.0 0.2 0.4 0.6 0.8 1.0
Dose [Gy]
60 40 20 0 20 40 60
X [mm]
60
40
20
0
20
40
60
Y 
[m
m
]
Gamma index analysis
0.0 0.5 1.0 1.5 2.0
Gamma index [ ]
0 50 100 150 200
Depth in water [mm]
0.0
0.2
0.4
0.6
0.8
1.0
In
te
gr
at
ed
 d
ep
th
 d
os
e,
 ID
D 
[G
y]
80MeV 180MeV
Measured Bragg peak
FRED Bragg peak
Fig. 2. Integrated depth dose distributions of proton pencil beams simulated in
Fred and obtained experimentally during the facility commissioning (left), an ex-
ample of transversal 2D dose distribution in isocentre plane obtained from Fred
MC simulations (middle left), measured with MatriXX detector in water (mid-
dle right) and a GI map computed from simulation and measurement using GI
(3%/2 mm) method (right). GI passing rate is 98.64%.
We are currently performing treatment planning studies to quantify the
biological range uncertainties exploring various biological models with vari-
able RBE and clinical data of patients treated in Krako´w.
An example of a selected Head and Neck (H&N) patient is presented
in fig. 3, where the radiobiological dose distributions computed with con-
stant and variable RBE using Fred as well as corresponding Dose Vol-
ume Histograms (DVHs) are shown. The MC calculation time for this case
was about 10 min (9·108 primary protons, 2·106 p+s tracking rate). The
mean dose to Planning Target Volume (PTV), calculated with Fred using
variable RBE model proposed by Carabe [8], is increased with respect to
the clinically applied constant RBE=1.1 assumption of about 3 Gy(RBE),
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whereas the maximum dose to the brain stem OAR increases by about
4 Gy(RBE). Our results show that incorporation of the variable RBE model
in patient dose calculation increases dose in PTV and OAR with respect
to constant RBE assumption. This is especially important when OARs are
very close to or overlap with the PTV as it occurs frequently in H&N pa-
tients. Considering variable RBE hypothesis in the proton therapy clinic
could be essential as increased biological dose deposited to OARs that ex-
ceeds clinical dose constraints can be potentially associated with increased
normal tissue complication probability an therefore an increased risk of
necrosis or secondary cancer.
Fig. 3. Left: the RBE-weighted dose with constant RBE=1.1, middle-left: the
RBE-weighted dose with variable RBE (Carabe model [8]), middle-right: dose
difference between constant and variable RBE. DVH for constant and variable
RBE for PTV and brain stem.
The use of the fast MC dose computation tool Fred for physical and
biological dose recalculation of patient treatment plans (retrospectively and
prospectively) can provide additional clinical information for medical physi-
cists and medical doctors and can potentially prevent inaccuracies in patient
treatment.
3. J-PET detector to address physical range uncertainties of
proton beams
The proton interactions with patient tissues allow range monitoring
during or just after the treatment detecting emitted secondary radiation.
Tracking of prompt-gamma, PET-gamma and secondary protons and neu-
trons are examples [9, 10, 11]. Prototype systems for prompt-gamma and
PET-gamma range monitoring were tested clinically and obtained satisfying
precision of Bragg-peak position monitoring on-line in the PBT treatment
room [12, 13, 14]. At the Jagiellonian University in Krako´w, a novel solution
for diagnostic PET imaging, Jagiellonian-PET (J-PET) is being developed.
A single detection unit of the J-PET scanner [15] consists of a 50 cm
long and 6×24 mm2 intersection size scintillator strip. The light pulses pro-
duced in the strip by 511 keV back-to-back photons propagate to its edges
where they are converted into electrical signals by photomultipliers (PMT).
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The interaction position of the photon with the detector is estimated from
the time difference between the PMT signals located at the ends of the
strip. A J-PET module consists of 13 scintillator strips read-out through a
single front-end electronics and a FPGA-based DAQ system. A modular,
lightweight and portable design of J-PET enables flexibility in detector con-
figuration and easy installation. Increasing the number of J-PET detector
layers increases the detection efficiency of the system.
We performed comprehensive MC simulations using the GATE toolkit
[16] and reconstructions of 3D β+ activity distributions using the CASTOR
software [17]. The aim was to characterize the sensitivity of the J-PET
for proton beam range detection. We investigated single and multi-layer
cylindrical and dual-head configurations of the J-PET modules that can be
possibly applied for in-room range monitoring. The list-mode TOF-MLEM
reconstruction (5 iterations with 500 ps TOF resolution without regulariza-
tion), takes into account random events, scatter, attenuation and normal-
ization corrections. Eventually, the reconstructed PET-activity profiles can
be correlated with the position of dose distal fall-off (Fig. 5, right) and used
for proton beam range monitoring.
Fig. 4. Single layer mod-
ular J-PET barrel with
isocentrically positioned
PMMA phantom.
In this manuscript, we present preliminary re-
sults for one of the investigated setup configura-
tions, i.e. a single layer J-PET barrel (fig. 4). Fig. 5
illustrates a cross-section through the centre of
the beam of 3D dose distribution deposited in a
5×5×20 cm3 PMMA phantom by 108 protons of
nominal energy 150 MeV (top left) and the same
cross-section of reconstructed 3D distribution of
β+ activity produced by the beam in the phantom
(bottom left). The activity map was reconstructed
in 5×5×5 mm3 voxel grid. The scintillator strips’
detection efficiency is taken into account in MC
simulations. The expected spatial and time res-
olutions of J-PET with wavelength-shifting strips
(WLS) [18] is taken into account through plastic
length discretization used in the simulations and
image reconstruction.
The fig. 5 (right) presents the MC simulated profiles of: (i) proton dose
deposition in the PMMA phantom, (ii) β+ activity produced in the phan-
tom and (iii) actual signal detected by J-PET barrel from β+ activity. The
results show that the J-PET detector is feasible to acquire the β+ activity
produced during proton therapy treatment and that the offline 3D recon-
struction of PET activity images is possible using CASTOR toolkit. The
characterization of J-PET sensitivity for proton beam range detection is
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currently an ongoing research activity.
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Fig. 5. The results of MC simulations. Top left: 2D distribution of dose deposited
by 150 MeV proton beam in PMMA phantom; bottom left: β+ activity distribution
detected in J-PET and reconstructed with CASTOR software; right: dose, β+
production in PMMA, reconstructed signal from β+ activity detected with J-PET.
4. Summary
Within the research projects conducted in the Institute of Nuclear Physics
PAN in Krako´w we investigate physical and biological range uncertainties
of proton beams through positron emission tomography (PET) based solu-
tions and Monte Carlo (MC) simulations. Taking advantage of the Fred
accuracy and time performance possible due to GPU acceleration we aim to
improve quality assurance and treatment planing in Krako´w PBT facility.
A Monte Carlo study of J-PET detector feasibility performed in the frame
of the project suggests that this technique might be considered as a novel
proton beam therapy range monitoring approach.
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